XPH – SPDR® S&P Pharmaceuticals ETF
SPDR® S&P Pharmaceuticals ETF (XPH) is a Health ETF, issued by State Street Investment Management, $439M in assets, 0.35% expense ratio.
Returns as of Oct 23, 2026: 1 week +1.4%, 1 year +28.9%.
Tracks S&P Pharmaceuticals Select Industry Index, sampling strategy to invest in pharmaceutical segment of S&P Total Market Index.
Top holdings
- MANE – Veradermics, Incorporated, 2.8%
- XERS – Xeris Pharmaceuticals Inc, 2.7%
- PCRX – Pacira BioSciences, Inc., 2.6%
- LLY – Eli Lilly and Company, 2.4%
- AMRX – Amneal Pharmaceuticals, Inc. Class A Common Stock, 2.4%
- PRGO – Perrigo Company PLC, 2.4%
- MAZE – Maze Therapeutics, Inc. Common Stock, 2.3%
- ZTS – Zoetis Inc, 2.3%
- PFE – Pfizer Inc, 2.3%
- ANIP – ANI Pharmaceuticals Inc, 2.2%
- RPRX – Royalty Pharma Plc, 2.2%
- VTRS – Viatris Inc, 2.2%
- SEPN – Septerna, Inc. Common Stock, 2.2%
- LGND – Ligand Pharmaceuticals Incorporated, 2.2%
- JNJ – Johnson & Johnson, 2.0%
- INVA – Innoviva Inc, 2.0%
- SUPN – Supernus Pharmaceuticals Inc, 2.0%
- DFTX – Definium Therapeutics, Inc., 2.0%
- COLL – Collegium Pharmaceutical Inc, 2.0%
- OGN – Organon & Co, 2.0%
- ELAN – Elanco Animal Health, 2.0%
- INDV – Indivior PLC Ordinary Shares, 2.0%
- MRK – Merck & Company Inc, 2.0%
- PBH – Prestige Brand Holdings Inc, 1.9%
- EWTX – Edgewise Therapeutics Inc, 1.9%